Yale Cancer Center researchers show promising new treatment for patients with myelodysplastic syndromes

A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.

Read more